Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Arefeh Rouhi is active.

Publication


Featured researches published by Arefeh Rouhi.


Journal of Immunology | 2006

Evidence for Epigenetic Maintenance of Ly49a Monoallelic Gene Expression

Arefeh Rouhi; Liane Gagnier; Fumio Takei; Dixie L. Mager

Although structurally unrelated, the human killer cell Ig-like (KIR) genes and the rodent lectin-like Ly49 genes serve similar functional roles in NK cells. Moreover, both gene families display variegated, monoallelic expression patterns established at the transcriptional level. DNA methylation has been shown to play an important role in maintenance of expression patterns of KIR genes, which have CpG island promoters. The potential role of DNA methylation in expression of Ly49 genes, which have CpG-poor promoters, is unknown. In this study, we show that hypomethylation of the region encompassing the Pro-2 promoter of Ly49a and Ly49c in primary C57BL/6 NK cells correlates with expression of the gene. Using C57BL/6 × BALB/c F1 hybrid mice, we demonstrate that the expressed allele of Ly49a is hypomethylated while the nonexpressed allele is heavily methylated, indicating a role for epigenetics in maintaining monoallelic Ly49 gene expression. Furthermore, the Ly49a Pro-2 region is heavily methylated in fetal NK cells but variably methylated in nonlymphoid tissues. Finally, in apparent contrast to the KIR genes, we show that DNA methylation and the histone acetylation state of the Pro-2 region are strictly linked with Ly49a expression status.


Epigenetics | 2010

Variable DNA methylation of transposable elements The case study of mouse Early Transposons

Daphne Reiss; Ying Zhang; Arefeh Rouhi; Max Reuter; Dixie L. Mager

Phenotypic variation stems from both genetic and epigenetic differences between individuals. In order to elucidate how phenotypes are determined, it is necessary to understand the forces that generate variation in genome sequence as well as its epigenetic state. In both contexts, transposable elements (TEs) may play an important role. It is well established that TE activity is a major generator of genetic variation, but recent research also suggests that TEs contribute to epigenetic variation. Stochastic epigenetic silencing of some TE insertions in mice has been shown to cause phenotypic variability between individuals. However, the prevalence of this phenomenon has never been evaluated. Here, we use 18 insertions of a mouse Endogenous Retrovirus (ERV) family, the early transposons (ETns), to detect insertion-dependent determinants of DNA methylation levels and variability between both cells and individuals. We show that the structure and age of insertions influence methylation levels and variability, resulting in a subgroup of loci that displays unexpectedly high variability in methylation and suggesting stochastic events during methylation establishment. Despite variation in methylation according to the age and structure of each locus, homologous CpG sites show similar tendencies in methylation levels across loci, emphasizing the role of the insertion’s sequence in methylation determination. Our results show that differences in methylation of ETns between individuals is not a sporadic phenomenon and support the hypothesis that ERVs contribute to phenotypic variability through their stochastic silencing.


Nucleic Acids Research | 2009

Evidence for high bi-allelic expression of activating Ly49 receptors.

Arefeh Rouhi; C. Benjamin Lai; Tammy P. Cheng; Fumio Takei; Wayne M. Yokoyama; Dixie L. Mager

Stochastic expression is a hallmark of the Ly49 family that encode the main MHC class-I-recognizing receptors of mouse natural killer (NK) cells. This highly polygenic and polymorphic family includes both activating and inhibitory receptor genes and is one of genomes fastest evolving loci. The inhibitory Ly49 genes are expressed in a stochastic mono-allelic manner, possibly under the control of an upstream bi-directional early promoter and show mono-allelic DNA methylation patterns. To date, no studies have directly addressed the transcriptional regulation of the activating Ly49 receptors. Our study shows differences in DNA methylation pattern between activating and inhibitory genes in C57BL/6 and F1 hybrid mouse strains. We also show a bias towards bi-allelic expression of the activating receptors based on allele-specific single-cell RT–PCR in F1 hybrid NK cells for Ly49d and Ly49H expression in Ly49h+/− mice. Furthermore, we have identified a region of high sequence identity with possible transcriptional regulatory capacity for the activating Ly49 genes. Our results also point to a likely difference between NK and T-cells in their ability to transcribe the activating Ly49 genes. These studies highlight the complex regulation of this rapidly evolving gene family of central importance in mouse NK cell function.


Biology of Blood and Marrow Transplantation | 2017

Thrombotic Microangiopathy after Allogeneic Stem Cell Transplantation: A Comparison of Eculizumab Therapy and Conventional Therapy

Stephan R. Bohl; Florian Kuchenbauer; Stefanie von Harsdorf; Nadine Kloevekorn; Stefan Schönsteiner; Arefeh Rouhi; Phyllis Schwarzwälder; Hartmut Döhner; Donald Bunjes; Martin Bommer

We report the results of a single-center analysis of a cohort of 39 patients treated between 1997 and 2016 for transplantion-associated thrombotic microangiopathy. We evaluated 2 subgroups of patients: 24 patients treated between 1997 and 2014 who received conventional therapy and 15 patients treated with the complement-inhibiting monoclonal antibody eculizumab between 2014 and 2016. The conventional therapy group was treated predominantly with defibrotide alone or in combination with plasmapheresis or rituximab. Despite an initial response rate of 61%, only 4 patients (16%) were long-term survivors, 2 of whom had a low-risk thrombotic microangiopathy without multiorgan damage. Progression of thrombotic micorangiopathy and bacterial/fungal infections contributed equally to treatment failure. The overall response rate in the eculizumab group was significantly higher, at 93%. In addition, we were able to stop eculizumab treatment in 5 patients (33%), all of whom had high-risk thrombotic microangiopathy, due to sustained recovery. Despite the very good response in the eculizumab-treated group, we did not observe a significant improved overall survival, due primarily to a high rate of infection-related mortality (70%). Therefore, further studies are needed to identify the optimal therapeutic management approach for transplantation-associated thrombotic microangiopathy to improve its dismal outcome.


Haematologica | 2017

Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia

Susanne Hirsch; Tamara J. Blätte; Sarah Grasedieck; Sibylle Cocciardi; Arefeh Rouhi; Mojca Jongen-Lavrencic; Peter Paschka; Jan Krönke; Verena I. Gaidzik; Hartmut Döhner; Richard F. Schlenk; Florian Kuchenbauer; Konstanze Döhner; Anna Dolnik; Lars Bullinger

In acute myeloid leukemia, there is growing evidence for splicing pattern deregulation, including differential expression of linear splice isoforms of the commonly mutated gene nucleophosmin (NPM1). In this study, we detect circular RNAs of NPM1 and quantify circRNA hsa_circ_0075001 in a cohort of NPM1 wild-type and mutated acute myeloid leukemia (n=46). Hsa_circ_0075001 expression correlates positively with total NPM1 expression, but is independent of the NPM1 mutational status. High versus low hsa_circ_0075001 expression defines patient subgroups characterized by distinct gene expression patterns, such as lower expression of components of the Toll-like receptor signaling pathway in high hsa_circ_0075001 expression cases. Global evaluation of circRNA expression in sorted healthy hematopoietic controls (n=10) and acute myeloid leukemia (n=10) reveals circRNA transcripts for 47.9% of all highly expressed genes. While circRNA expression correlates globally with parental gene expression, we identify hematopoietic differentiation-associated as well as acute myeloid leukemia subgroup-specific circRNA signatures.


Oncotarget | 2017

Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.

Arefeh Rouhi; Christina Miller; Sarah Grasedieck; Stefanie Reinhart; Britta Stolze; Hartmut Döhner; Florian Kuchenbauer; Lars Bullinger; Stefan Fröhling; Claudia Scholl

Inhibition of the HSP90 chaperone results in depletion of many signaling proteins that drive tumorigenesis, such as downstream effectors of KRAS, the most commonly mutated human oncogene. As a consequence, several small-molecule HSP90 inhibitors are being evaluated in clinical trials as anticancer agents. To prospectively identify mechanisms through which HSP90-dependent cancer cells evade pharmacologic HSP90 blockade, we generated multiple mutant KRAS-driven cancer cell lines with acquired resistance to the purine-scaffold HSP90 inhibitor PU-H71. All cell lines retained dependence on HSP90 function, as evidenced by sensitivity to short hairpin RNA-mediated suppression of HSP90AA1 or HSP90AB1 (also called HSP90α and HSP90β, respectively), and exhibited two types of genomic alterations that interfere with the effects of PU-H71 on cell viability and proliferation: (i) a Y142N missense mutation in the ATP-binding domain of HSP90α that co-occurred with amplification of the HSP90AA1 locus, (ii) genomic amplification and overexpression of the ABCB1 gene encoding the MDR1 drug efflux pump. In support of a functional role for these alterations, exogenous expression of HSP90α Y142N conferred PU-H71 resistance to HSP90-dependent cells, and pharmacologic MDR1 inhibition with tariquidar or lowering ABCB1 expression restored sensitivity to PU-H71 in ABCB1-amplified cells. Finally, comparison with structurally distinct HSP90 inhibitors currently in clinical development revealed that PU-H71 resistance could be overcome, in part, by ganetespib (also known as STA9090) but not tanespimycin (also known as 17-AAG). Together, these data identify potential mechanisms of acquired resistance to small molecules targeting HSP90 that may warrant proactive screening for additional HSP90 inhibitors or rational combination therapies.


Leukemia Research | 2018

The Endothelin receptor type A is a downstream target of Hoxa9 and Meis1 in Acute Myeloid Leukemia

Laleh S. Arabanian; Pegah Johansson; Anna Staffas; Tina Nilsson; Arefeh Rouhi; Linda Fogelstrand; Lars Palmqvist

Endothelin receptor type A (EDNRA) is known as a mediator of cell proliferation and survival. Aberrant regulation of EDNRA has been shown to play a role in tumor growth and metastasis. Using a global gene expression screen, we found that expression of Ednra was upregulated in murine leukemia inducing cells co-expressing Hoxa9 and Meis1 compared to cells only expressing Hoxa9. The aim of this study was to explore the role of Ednra in leukemogenesis further. In a murine bone marrow transplantation model, mice transplanted with cells overexpressing Ednra and Hoxa9 succumbed to leukemia significantly earlier than mice transplanted with cells overexpressing Hoxa9 only. Furthermore, overexpression of Ednra led to increased proliferation and resistance to apoptosis of bone marrow cells in vitro. We could also show that Meis1 binds to the Ednra promoter region, suggesting a regulatory role for Meis1 in Ednra expression. Taken together, our results suggest a role for Ednra in Hoxa9/Meis1-driven leukemogenesis.


Blood | 2017

FOXtrotting with PUMILIOs

Arefeh Rouhi; Florian Kuchenbauer

In this issue of Blood , [Naudin et al][1] investigated the functional relevance of PUMILIO 1 and 2 (PUM1 and PUM2), 2 highly conserved RNA-binding proteins (RBPs) and members of the PUM and FBF (PUF) family of posttranscriptional regulators, in early hematopoiesis and acute myeloid leukemia (AML).[


Expert Review of Hematology | 2011

Stem cells and beyond: report on the 40th Annual Scientific Meeting of the International Society of Experimental Hematology

Arefeh Rouhi; Christian Buske

The 40th Annual Scientific Meeting of the International Society of Experimental Hematology and Stem Cells was held in beautiful Vancouver, Canada, and was chaired by David Scadden, Gerald de Haan and Peter Lansdorp. Topics such as hematopoietic stem cell biology, development, aging, microenvironment, signaling, genomics and transcriptional control in the context of normal and malignant hematopoiesis were addressed by key speakers in the field.


Molecular Biology and Evolution | 2002

The opitz syndrome gene mid1 is transcribed from a human endogenous retroviral promoter.

Josette-Renée Landry; Arefeh Rouhi; Patrik Medstrand; Dixie L. Mager

Collaboration


Dive into the Arefeh Rouhi's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

R. Keith Humphries

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Dixie L. Mager

University of British Columbia

View shared research outputs
Top Co-Authors

Avatar

Anna Staffas

Sahlgrenska University Hospital

View shared research outputs
Researchain Logo
Decentralizing Knowledge